HealthDay News — For persons receiving dialysis, the antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wanes through five to six months and is associated with a risk for breakthrough infection, according to a study published online Dec. 14 in the Annals of Internal Medicine.
Shuchi Anand, M.D., from Stanford University in Palo Alto, California, and colleagues determined longitudinal antibody-based response after SARS-CoV-2 vaccination among 4,791 patients receiving dialysis. Antibodies to the receptor-binding domain (RBD) of SARS-CoV-2 were measured from plasma. Each breakthrough case was matched to five control patients to evaluate whether peak or prebreakthrough RBD values were associated with breakthrough infection in a nested case-control analysis.
Of the 4,791 patients, 2,563 were vaccinated as of Sept. 14, 2021. The researchers found that among the vaccinated patients, the estimated proportion with an undetectable RBD response increased from 6.6 to 20.2 percent at 14 to 30 days after vaccination and five to six months after vaccination, respectively. There was a decrease in the estimated median index values, from 91.9 at 14 to 30 days after vaccination to 8.4 at five to six months after vaccination. Fifty-six patients had breakthrough infections, with samples collected a median of 21 days before infection. Prebreakthrough index RBD values of <10 and 10 to <23 were associated with increased odds of breakthrough infection compared with a value of ≥23 (rate ratios, 11.6 and 6.0, respectively).
“Serologic testing using commercially available high-throughput assays could inform vaccination and enhanced mitigation strategies and potentially improve uptake of additional vaccination doses in immunocompromised and other high-risk populations,” the authors write.
Several authors disclosed financial ties to the pharmaceutical industry and to Ascend Clinical Laboratory.